Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.


TSXV:ARCH - Post by User

Post by Viking2233on Apr 26, 2024 9:49am
162 Views
Post# 36009108

Algorithms back in control

Algorithms back in control

We had a nice run over the last 6 months with the share price going from $1 to $2.56. We had lits of material news released during this time frame. We dosed our first patient for the AKI phase 2 trial and announced another trial to commence in the summer with our repurpised drug.

We now return to a silent period as we continue to dose patients across 6 Turkish locations and soon to commence in 3 Canadian sites.

We now sit and wait as the trials commence and dsta collected. 


The lack of buying has settled in as the big boys wait for data to signal positive results, the downside is that this lack data provides a very quiet period and breeds ideal environment for the Algorithms to take back control and manipulate the stock based on absolutely nothing. It is hard to watch the share price eroded daily by these banksters or should I say gangsters.

We are again beliw $100M usd market cap which in itself is ridiculous when you look at the science and compare Arch to similar staged companies. We should be well above $10 at this stage but our time will come, as they say "Patience is a virtue"

Good luck to all the shareholders who are long!

<< Previous
Bullboard Posts
Next >>